Affymetrix, BioRealm, RUCDR Ally
News Jul 08, 2015
The samples will be genotyped using the BioRealm SmokeScreen array, a genome-wide array that looks at more than 1,000 addiction-related genes and which was developed in conjunction with NIDA's Genetics Consortium and Affymetrix.
"Because of the SmokeScreen array, we have the ability to reveal genetic information previously hidden in NIDA's samples," RUCDR COO Andrew Brooks said in a statement. "It is a validated platform that will become a crucial tool in advancing addiction research and moving the field towards personalized treatment."
The NIDA biobank contains more than 50,000 samples collected from human subjects in agency-funded research, and is maintained at Rutgers University by RUCDR, a unit of the school's Human Genetics Institute of New Jersey. In May of 2014, RUCDR received at $19 million grant to expand the services it provides to NIDA scientists.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.